A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
393actual
Sites
88
Countries
Australia, Belgium, Canada +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-10 | actual | When the study began enrolling |
| Primary completion | 2026-03-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-19 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate Plaque Psoriasis
Interventions
- Drug: Risankizumab
- Drug: Deucravacitinib
Primary outcomes
what the primary-completion date above is the date OFPeriod A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90)
measured At Week 16
Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) with at least 2-grade improvement from Baseline
measured Baseline, Week 16
Period B: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) in the Intent to Treat Population for non-responders in Period B (ITT_B_NR).
measured At Week 52
Number of Participants Experiencing Adverse Events (AEs)
measured Baseline up to 73 Weeks
Publications
- PMID 42143644 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed